Cytochrome P450 profile of colorectal cancer: Identification of markers of prognosis

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3758-3765

  Kumarakulasingham, Meera ^a   Rooney, Patrick H ^a,b   Dundas, Sinclair R ^a   Telfer, Colin ^b   Melvin, William T ^b   Curran, Stephanie ^a   Murray, Graeme I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Auvation Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN; CYTOCHROME 39; CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOCHROME P450 2A; CYTOCHROME P450 2B; CYTOCHROME P450 2F1; CYTOCHROME P450 2S1; CYTOCHROME P450 2U1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 4V2; STEROL 14ALPHA DEMETHYLASE; TUMOR MARKER; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; MICROSCOPY; MULTIGENE FAMILY; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

AGED; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 18844370604     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1848     Document Type: Article

References (45)

1. Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353:391-9.
2. Gill S, Thomas RR, Goldberg RM. New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol 2003;4:393-403.
3. Jass JR. Pathogenesis of colorectal cancer. Surg Clin North Am 2002;82:891-904.
4. Robbins DH, Itzkowitz SH. The molecular and genetic basis of colon cancer. Med Clin North Am 2002;86:1467-95.
5. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-62.
6. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3:561-97.
7. Murray GI. The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 2000;192:419-26.
8. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003;43:149-73.
9. Guengerich FP, Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 1998;400:201-13.
10. Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 1997;376:153-60.
11. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-31.
12. Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002;8:1335-47.
13. Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40:523-30.
14. McFadyen MCE, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004;3:363-71.
15. Rooney PH, Telfer C, McFadyen MCE, Melvin WT, Murray GI. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets 2004;4:257-65.
16. Maecker B, Sherr DH, Vonderheide RH, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102:3287-94.
17. Patterson LH. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 2002;34:581-92.
18. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000;83:1589-93.
19. Murayama N, Sai K, Nakajima Y, et al. Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res 2001;92:524-8.
20. Chun YJ, Kim S. Discovery of cytochrome P4501B1 inhibitors as new promising anti-cancer agents. Med Res Rev 2003;23:657-68.
21. Chen L, Waxman DJ. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 2002;8:1405-16.
22. Kan O, Kingsman S, Naylor S. Cytochrome P450-based cancer gene therapy: current status. Expert Opin Biol Ther 2002;2:857-68.
23. McFadyen MCE, Breeman S, Payne S, et al. Immunohistochemical localisation of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 1999;47:1457-64.
24. Murray GI, Barnes TS, Sewell HF, Ewen SWB, Melvin WT, Burke MD. The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol 1988;25:465-75.
25. Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 1998;56:377-87.
26. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is overexpressed by colorectal cancer and correlates with poor survival. J Pathol 2005;205:74-81.
27. Rooney PH, Boonsong A, McFadyen MCE, et al. The candidate oncogene ZNF217 is frequently amplified in colon cancer. J Pathol 2004;204:282-8.
28. Wright CL, Stewart ID. Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol 2003;27:1393-406.
29. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995;36:259-67.
30. McKay JA, Murray GI, Weaver RJ, Ewen SWB, Melvin WT, Burke MD. Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut 1993;34:1234-9.
31. Rylander T, Neve EP, Ingelman-Sundberg M, Oscarson M. Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem Biophys Res Commun 2001;281:529-35.
32. Rivera SP, Saarikoski ST, Hankinson O. Identification of a novel dioxin-inducible cytochrome P450. Mol Pharmacol 2002;61:255-9.
33. Smith G, Wolf CR, Deeni YY, et al. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 2003;361:1336-43.
34. Martinez C, Garcia-Martin E, Pizarro RM, Garcia-Gamito FJ, Agundez JA. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 2002;87:681-6.
35. Massaad L, deWaziers I, Ribrag V, et al. Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res 1992;52:6567-75.
36. Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet 2001;357:1673-4.
37. Gibson P, Gill JH, Khan PA, et al. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther 2003;2:527-34.
38. Stromstedt M, Rozman D, Waterman MR. The ubiquitously expressed human CYP51 encodes lanosterol 14 α-demethylase, a cytochrome P450 whose expression is regulated by oxysterols. Arch Biochem Biophys 1996;329:73-81.
39. Debeljak N, Fink M, Rozman D. Many facets of mammalian lanosterol 14α-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. Arch Biochem Biophys 2003;409:159-71.
40. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-74.
41. Quaranta V. Motility cues in the tumor microenvironment. Differentiation 2002;70:590-8.
42. Chuang SS, Helvig C, Taimi M, et al. CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes ω- and (ω-1)-hydroxylation of fatty acids. J Biol Chem 2004;279:6305-14.
43. Karlgren M, Backlund M, Johansson I, Oscarson M, Ingelman-Sundberg M. Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. Biochem Biophys Res Commun 2004;315:679-85.
44. McFadyen MCE, Cruickshank ME, Miller ID, et al. Cytochrome P450 CYP1B1 is overexpressed in primary and secondary ovarian cancer. Br J Cancer 2001;85:242-6.
45. Lane CS, Nisar S, Griffiths WJ, et al. Identification of cytochrome P450 enzymes in human colorectal metastases and the surrounding liver: a proteomic approach. Eur J Cancer 2004;40:2127-34.